David Atuahene

Ten commercial mushroom products, sourced from resellers and labelled for veterinary use, were subjected to simple quantitative and qualitative polysaccharide analysis methods to differentiate products containing only mushrooms (the fruiting bodies of the fungal life-cycle) from those that include the whole solid fermentation resulting from the fungal mycelium of cereal grain. The therapeutic benefits of fungi are often attributed to their β-glucan content, which, unlike cereal grain β glucans, is uniquely characterized by 1,3-1,6 β glycosidic linkages. Fungal polysaccharide markers were used to distinguish mushroom-containing products from grain-based mycelial products in this study, which highlighted the compositional variability in marketplace products. Ten products labelled for pet use, and one for human use, were subjected to a multifaceted analytical approach by enzymatic quantification of α- and β-glucans and starch, and Lugol’s iodine staining for starch detection. The resulting analyses identified two distinct product profiles: 1) polysaccharide profiles consistent with mushrooms, exhibiting high β-glucan and low α-glucan content and 2) products consistent with fermentation of cereal grains by fungal mycelium that have lower levels of β-glucans, higher levels of α-glucans, and a strong positive iodine-starch test. This study provides objective, evidence-based criteria for differentiation of these product profiles; some products labelled as mushroom-derived contained predominantly grain. This method can be adapted to assess other fungal-derived products and verify the authenticity of mushroom-based veterinary products.

The extensive application of antibiotics in poultry production has resulted in the emergence of resistant bacteria, which pose a great threat to the health of birds and humans. In this review, the literature is searched using databases such as PubMed, Scopus, Web of Science, and Google Scholar. Studies concerning antimicrobial resistance in poultry, the One Health approach, and alternative strategies to antibiotics are included, while studies not in English, opinion-based papers, and studies not related to poultry or AMR are excluded. This review explores the increasing challenges of antibiotic resistance in poultry, emphasizing the One Health framework related to animal, human, and environmental health. The risks of zoonotic transmission from poultry, the mode of development of resistance, and alternative antibiotics (comprising probiotics, prebiotics, enzymes, and essential oils) are the key topics discussed. This review further touches on critical barriers in fighting antibiotic resistance, which include economic constraints, a lack of awareness, and coordination challenges. This study highlights regulatory and consumer-driven changes in antibiotic use. The poultry industry can reduce the use of antibiotics by adopting the One Health approach and implementing evidence-based alternatives that support productivity. However, sustainable solutions require further research, policy reforms, and collaboration across sectors.

The cardinal Physiology of Gut Health in monogastric animals such as swine and poultry is vital. It is critical for digestive efficiency, immune status, and production levels. This system is related not only to the digestion and absorption of nutrients from feed ingredients contributing to growth and feed utilization efficiency but also to having a strategic microbiota that supports immunity and pathogen resistance, as well as metabolic support. Gut disease, for example, bacterial, viral, or parasitic infection, diet, or stress, can reduce nutrient digestion and absorption. They can also suppress the immune system and render patients more prone to disease. These are efficiency degradations and increase veterinary and husbandry costs. In addition, nutrient absorption because of deteriorated gut health can affect the environment in different ways: removal of nutrients through leaching and the release of gases (including CH₄ and NH₄). These pressures have led to a focus on the gut in animal research to improve the welfare of animals and ensure sustainable practices in animal production. Recent studies have included the use of probiotics, prebiotics, and other feed additives to enhance the positive effects of the gut microbiota. These are also intervention points to increase nutrient absorption and animal well-being, in turn sustainability. Such approaches are expected to promote a stable microbial community with less dependence on the use of antibiotics, less waste generation, and less environmental impact from animal farming. This review provides a critical evaluation of the current literature on gut health in monogastric livestock, with pigs and poultry as the principal focus. We also considered the impact of gut health on production efficiency and Environmental sustainability. Current progress in nutritional modulation of gut health for increased productivity, enhanced animal welfare, and better profitability are presented. Gut-related biological mechanisms are linked to practical nutritional strategies, and subsequently to animal welfare, production efficiency, and environmental effects, offering a coherent concept for moving from mechanism to system-level sustainability.

Background: Moringa oleifera is one of the most nutrient-packed species, commonly known as the drumstick tree or miracle tree, and has garnered substantial popularity for its health benefits, phytochemical profile, and therapeutic potential. Moringa oleifera is a plant that is native to the Indian subcontinent and has been used in traditional medicine for thousands of years owing to its nutritional and therapeutic properties. Methods: The leaves, seeds, pods, roots, and flowers of this plant are enriched with a wide range of bioactive compounds such as flavonoids, alkaloids, vitamins, minerals, and essential amino acids. Therefore, it is considered a reservoir crop for both nutritional and medicinal applications. Result: The recent rediscovery of the plant is at the forefront of changes in nutrition, medicine, and public health. Owing to its varied clinical applications, the plant is a potential candidate for research in new drug development and functional foods. Conclusions: Potential applications of Moringa compounds in the treatment of chronic diseases include antioxidant, anti-inflammatory, antimicrobial (bacterial or fungal), and anticancerous effects. In this review, various phytochemical extraction techniques, therapeutic properties, and applications are discussed.

Companion animals such as dogs and cats play a crucial role in modern families. Their overall health is significantly influenced by their gut health, with many health disorders arising from disturbances in the gut microbiome. Our review highlights the ability of probiotics and nutraceuticals to modify the gut microbiota and enhance gastrointestinal health in canine and feline species. We investigated the effects of probiotics and natural antioxidant molecules on digestion, immunological response, and barrier integrity in gastrointestinal health studies concerning dogs and cats. The analysis indicated that probiotics influence gut microbiota composition in a positive manner, enhance digestion, augment the immune response, and help to maintain barrier integrity. Additionally, natural products with antioxidant molecules showed the potential to improve gut health and protect pets from various illnesses. We concluded by advocating the need for more studies in this direction to fully understand their effects and optimize their use in veterinary medicine.

This study aimed to determine the impact of a novel formulation of a supplement composed of the natural ingredients, bromelain, quercetin, and Lentinula edodes, on the gut microbiota of healthy adult dogs. Adult healthy female dogs were administered either a placebo (CTR, n = 15) or the supplement (TRT, n = 15) over 28 days. Stool samples were collected for 16S rRNA sequencing before supplement administration (T0), at completion of supplement administration (T28), and one week after the end of supplement administration (T35) to characterize changes in the gut microbial communities. QIIME was used to determine both alpha- and beta-diversity, and ANCOM-BC was used to identify differences in taxonomic abundances before and after supplementation. We found a significant decrease in overall diversity in the CTR group but no significant differences in overall diversity in the TRT group over time. Furthermore, we found differences in the abundance of several taxa in both the CTR and TRT groups, but differences in the abundance of beneficial bacteria were more pronounced in the TRT group. Specifically, we found increases in the abundance of sequences belonging to the genera Bifidobacterium, Lactobacillus, and Pediococcus at T28 in the TRT group with significant increases in Bifidobacterium and Lactobacillus persisting at T35 when compared to T0. Importantly, members of these genera are considered important for their anti-inflammatory properties, vital for fostering a balanced and robust gut microbiota in dogs. The results of our study show the potential of our supplement to selectively enhance specific beneficial bacterial taxa, offering a targeted approach to modulating the gut microbiome without causing disruptions to the overall equilibrium.

This study aimed to determine the impact of a novel formulation of a supplement composed of the natural ingredients: bromelain, quercetin, and Lentinula edodes, on the gut microbiota of healthy adult dogs. Adult healthy female dogs were administered either a placebo (CTR, n = 15) or the supplement (TRT, n=15) over 28 days. Stool samples were collected for 16S rRNA sequencing before supplement administration (T0), at completion of supplement administration (T28), and one week after the end of supplement administration (T35) to characterize changes in the gut microbial communities. QIIME was used to determine both alpha- and beta-diversity and ANCOM-BC was used to identify differences in taxonomic abundances before and after supplementation. We found a significant decrease in overall diversity in CTR group, but no significant differences in overall diversity in the TRT group over time. Furthermore, we found differences in the abundance of several taxa in both CTR and TRT groups but differences in abundance of beneficial bacteria were more pronounced in TRT group. Specifically, we found increases in the abundance of sequences belonging to the genera Bifidobacterium, Lactobacillus, and Pediococcus at T28 in the TRT group with significant increases in Bifidobacterium and Lactobacillus persisting at T35 when compared to T0. Importantly, members of these genera are known to be pro anti-inflammatory and associated with a healthy gut microbiota in dogs. The results of our study show the potential of our supplement to selectively enhance specific beneficial bacterial taxa, offering a targeted approach to modulating the gut microbiome without causing disruptions to the overall equilibrium.

There was an error in the original publication

Overweight and obese dogs can develop metabolic dysfunction, characterized by an inflammatory response and involvement of liver functions. If a modulation of the gut microbiome and its interaction with the gut–liver axis is implicated in the development of metabolic dysfunction, exploration becomes necessary. Over the past decade, diverse therapeutic approaches have emerged to target pathogenic factors involved in metabolic dysfunction. This study investigated the impact of a supplement with hepatoprotective activity, containing extracts of Silybum marianum, prebiotics, probiotics, n-3 polyunsaturated fatty acids, vitamins, and minerals on hematological markers of liver functions and inflammation, as well as on the intestinal microbiota of 10 overweight adult dogs over a 35-day time span. Animals underwent clinical and laboratory evaluations every 7 days, both before the administration of the supplement (T0) and after 7, 14, 21, 28, and 35 days (T1, T2, T3, T4, and T5). In comparison to T0, a significant (p < 0.05) decrease in ALP, glucose, direct bilirubin, and CRP was observed from T3 to T5. The alpha diversity of the fecal microbiota significantly decreased (p < 0.05) only at T1, with high variability observed between dogs. Total short-chain fatty acid and lactic acid were also lower at T1 (p < 0.05) compared to the other times of sampling. The beta diversity of the fecal microbiota failed to show a clear pattern in relation to the sampling times. These results of blood parameters in overweight dogs show a reduction of the inflammation and an improvement of metabolic status during the study period, but the effective contribution of the supplement in this clinical outcome deserves further investigation. Furthermore, the considerable individual variability observed in the microbiome hinders the confident detection of supplement effects.